{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.95","value":"2.9"},{"groupId":"OG001","spread":"12.10","value":"1.8"},{"groupId":"OG002","spread":"10.70","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"142"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.92","value":"2.6"},{"groupId":"OG001","spread":"11.18","value":"2.9"},{"groupId":"OG002","spread":"9.71","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"155"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.19","value":"2.9"},{"groupId":"OG001","spread":"11.79","value":"3.5"},{"groupId":"OG002","spread":"11.54","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"157"},{"groupId":"OG002","value":"124"}],"units":"Participants"}],"title":"Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.00","value":"2.4"},{"groupId":"OG001","spread":"11.78","value":"2.1"},{"groupId":"OG002","spread":"11.14","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"141"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.23","value":"3.0"},{"groupId":"OG001","spread":"11.44","value":"1.4"},{"groupId":"OG002","spread":"10.41","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"84"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.27","value":"7.7"},{"groupId":"OG001","spread":"13.70","value":"7.4"},{"groupId":"OG002","spread":"14.10","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"136"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"description":"Vital signs included blood pressure and pulse rate. Changes from baseline in sitting pulse rate were summarized.","dispersionType":"Standard Deviation","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEAN","populationDescription":"'Number of Participants Analyzed' is based on the safety analysis set, which included all participants who received at least 1 dose of study treatment. 'Number Analyzed' included the number of participants in the safety analysis set with at least a baseline and post-baseline assessment at the visit.","reportingStatus":"POSTED","timeFrame":"From screening to the end of treatment/withdrawal visit, up to 2.7 years, based on cutoff date: 19 September 2018.","title":"Change From Baseline in Vital Signs - Pulse Rate","type":"SECONDARY","unitOfMeasure":"bpm"}